{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:31:16Z","timestamp":1785544276574,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Suqian Sci & Tech Program","award":["S202006"],"award-info":[{"award-number":["S202006"]}]},{"name":"Suqian Sci & Tech Program","award":["K202014"],"award-info":[{"award-number":["K202014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-024-01066-x","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:15:13Z","timestamp":1714569313000},"page":"1107-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor"],"prefix":"10.1007","volume":"37","author":[{"given":"Xiaoyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianggang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-3881","authenticated-orcid":false,"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei J, Long L, Zheng W, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576:471\u20136.","journal-title":"Nature"},{"key":"1066_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071\u201380.","journal-title":"Cell Death Differ"},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12253-009-9241-2","volume":"16","author":"A Vuletic","year":"2010","unstructured":"Vuletic A, Konjevic G, Milanovic D, Ruzdijic S, Jurisic V. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0\/G1 arrested HL-60 cells. Pathol Oncol Res. 2010;16:393\u2013401.","journal-title":"Pathol Oncol Res"},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","volume":"137","author":"S Maji","year":"2018","unstructured":"Maji S, Panda S, Samal SK, et al. Bcl-2 Antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res. 2018;137:37\u201375.","journal-title":"Adv Cancer Res"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0962-8924(94)90053-1","volume":"4","author":"G Nunez","year":"1994","unstructured":"Nunez G, Clarke MF. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol. 1994;4:399\u2013403.","journal-title":"Trends Cell Biol"},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh N, Lee YG, Shestova O, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10:552\u201367.","journal-title":"Cancer Discov"},{"key":"1066_CR8","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee YG, Guruprasad P, Ghilardi G, et al. Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov. 2022;12:2372\u201391.","journal-title":"Cancer Discov"},{"key":"1066_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1209","author":"Y Yang","year":"2017","unstructured":"Yang Y, Kohler ME, Chien CD, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aag1209.","journal-title":"Sci Transl Med."},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","volume":"71","author":"JC Lee","year":"2011","unstructured":"Lee JC, Hayman E, Pegram HJ, et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011;71:2871\u201381.","journal-title":"Cancer Res"},{"key":"1066_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/mt.2011.256","volume":"20","author":"E Lanitis","year":"2012","unstructured":"Lanitis E, Poussin M, Hagemann IS, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20:633\u201343.","journal-title":"Mol Ther"},{"key":"1066_CR12","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138\u201348.","journal-title":"Blood"},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335.","journal-title":"J Exp Med"},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.4049\/jimmunol.1103019","volume":"188","author":"P Spear","year":"2012","unstructured":"Spear P, Barber A, Rynda-Apple A, Sentman CL. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. J Immunol. 2012;188:6389\u201398.","journal-title":"J Immunol"},{"key":"1066_CR15","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 2018;23:2130\u201341.","journal-title":"Cell Rep"},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.18632\/oncotarget.27599","volume":"11","author":"G Chagoya","year":"2020","unstructured":"Chagoya G, Kwatra SG, Nanni CW, et al. Efficacy of osimertinib against EGFRvIII+ glioblastoma. Oncotarget. 2020;11:2074\u201382.","journal-title":"Oncotarget"},{"key":"1066_CR17","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.4161\/21645515.2014.983002","volume":"10","author":"M Paff","year":"2014","unstructured":"Paff M, Alexandru-Abrams D, Hsu FP, Bota DA. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Hum Vaccin Immunother. 2014;10:3322\u201331.","journal-title":"Hum Vaccin Immunother"},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","volume":"36","author":"Y Kagoya","year":"2023","unstructured":"Kagoya Y. Cytokine signaling in chimeric antigen receptor T cell therapy. Int Immunol. 2023;36:49\u201356.","journal-title":"Int Immunol"},{"key":"1066_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00232-010-9309-7","volume":"239","author":"V Jurisic","year":"2011","unstructured":"Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-alpha induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239:115\u201322.","journal-title":"J Membr Biol"},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14789450.2020.1845654","volume":"17","author":"V Jurisic","year":"2020","unstructured":"Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteom. 2020;17:663\u201374.","journal-title":"Expert Rev Proteom"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1002\/ctm2.1141","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, Qu Y, Cheng L, et al. Engineering chimeric antigen receptor T cells for solid tumour therapy. Clin Transl Med. 2022;12:e1141.","journal-title":"Clin Transl Med"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-024-01066-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-024-01066-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-024-01066-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T07:10:35Z","timestamp":1719126635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-024-01066-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s13577-024-01066-x","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}